Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Revenue | $23.8M | $55.3M | $31.5M | $32.7M | $29.1M | $8.26M |
| Revenue growth | — | 132.3% | -43.0% | 3.8% | -11.2% | -71.6% |
| Operating income | -$1.07B | -$1.35B | -$907M | $4.50B | -$1.00B | -$515M |
| Operating margin | -4500.5% | -2444.8% | -2875.9% | 13746.9% | -3453.3% | -6235.7% |
| Net income | -$809M | -$845M | -$1.01B | $4.35B | -$172M | -$300M |
| Net margin | -3400.9% | -1528.9% | -3200.2% | 13294.2% | -592.0% | -3629.2% |
| EPS (diluted) | -$1.28 | -$1.26 | -$1.42 | $5.23 | -$0.24 | -$0.54 |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$552M | -$678M | -$843M | -$765M | -$839M | -$750M |
| Capital expenditures | $5.81M | $17.4M | $12.7M | $1.38M | $4.60M | $8.21M |
| Free cash flow | -$558M | -$695M | -$856M | -$767M | -$844M | -$759M |
| Share buybacks | — | — | $0.00 | $0.00 | $1.29B | — |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.06B | $2.06B | $1.68B | $6.49B | $2.72B | $1.42B |
| Total assets | $2.59B | $2.59B | $2.39B | $7.22B | $5.44B | $5.71B |
| Total liabilities | $528M | $524M | $782M | $774M | $250M | $416M |
| Long-term debt | $170M | $210M | $376M | $431M | — | — |
| Shareholders' equity | $1.80B | $1.66B | $1.16B | $5.97B | $4.69B | $4.53B |
| Retained earnings | -$1.92B | -$2.76B | -$3.77B | $576M | $116M | -$502M |
| Shares (wtd avg diluted) | 652M | 670M | 713M | 831M | 725M | 694M |
Every figure is extracted from Roivant Sciences Ltd.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.